4-(3-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)propyl)morpholine

ID: ALA4762627

PubChem CID: 58514002

Max Phase: Preclinical

Molecular Formula: C17H21Cl2N3O

Molecular Weight: 354.28

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1cc(CCCN2CCOCC2)nn1-c1ccc(Cl)c(Cl)c1

Standard InChI:  InChI=1S/C17H21Cl2N3O/c1-13-11-14(3-2-6-21-7-9-23-10-8-21)20-22(13)15-4-5-16(18)17(19)12-15/h4-5,11-12H,2-3,6-10H2,1H3

Standard InChI Key:  ABPFXMWOQGUVCF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   17.0302  -16.7868    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.6744  -16.2794    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.3909  -15.5098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5714  -15.5417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3485  -16.3309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8452  -14.8306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6606  -14.8844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1150  -14.2051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0618  -17.6018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3689  -18.0370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8173  -18.7943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7825  -17.9799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1238  -19.2345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4021  -18.8526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7107  -19.2883    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   17.1560  -20.0511    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   15.5817  -16.6134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9304  -14.2590    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.2844  -14.9923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0961  -15.0478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5541  -14.3706    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.1944  -13.6358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.3766  -13.5782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  1  1  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  9 10  2  0
 10 14  1  0
 13 11  1  0
 11 12  2  0
 12  9  1  0
  1  9  1  0
 13 14  2  0
 14 15  1  0
 13 16  1  0
  5 17  1  0
  8 18  1  0
 18 19  1  0
 18 23  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4762627

   4-[3-[1-(3,4-Dichlorophenyl)-5-methylpyrazol-3-yl]propyl]morpholine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 354.28

Molecular Weight (Monoisotopic): 353.1062

AlogP: 3.75

#Rotatable Bonds: 5

Polar Surface Area: 30.29

Molecular Species: NEUTRAL

HBA: 4

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.06

CX LogP: 3.80

CX LogD: 3.63

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.82

Np Likeness Score: -2.25

References

1. Díaz JL,García M,Torrens A,Caamaño AM,Enjo J,Sicre C,Lorente A,Port A,Montero A,Yeste S,Álvarez I,Martín M,Maldonado R,de laPuente B,Vidal-Torres A,Cendán CM,Vela JM,Almansa C.  (2020)  EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,  63  (23): [PMID:33237785] [10.1021/acs.jmedchem.0c01575]

Source

Source(1):

• Scientific Literature